Efficacy and safety of rhLTα-Da with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-labelled, controlled, phase IIb trial.

Yuhong Li, Wenqi Jiang, Feng‐Hua Wang, Guoping Sun, Jianhua Chen, Lin Cheng, Wei Liu, Rongsheng Zheng, Helong Zhang, Haitao Lan, Jun Qi, Yangqing Liu, Yanming Deng, Heng Zhao, Jian Xiong, Qing XuJournal of Clinical Oncology 2016 · DOI

Abstract

4036 Background: Recombinant human lymphotoxin-α derivative (rhLTα-Da) is the LTα derivative without N-terminal 27 amino acid residues. Our prior studies showed that the addition of rhLTα-Da to cisplatin-based treatment was tolerable and had an encouraging response rate in metastatic esophageal squamous cell carcinoma (mESCC). This randomized, multicenter, controlled, phase II b trial was conducted to evaluate the efficacy and safety of rhLTα-Da with cisplatin and fluorouracil (PF) as the first-line therapy for mESCC (ChiCTR-TRC-11001197). Methods: Patients from 15 centers in China were randomly assigned (1:1:1) into three arms (arm A, PF + 10 μg/m2/d rhLTα-Da; arm B, PF + 20 μg/m2/d rhLTα-Da, arm C, PF alone). The primary endpoints included progression-free survival (PFS) and confirmed overall response rate (ORR). An explanatory analysis was performed to evaluate the role of serum tumor necrosis factor receptor-II (TNFR-II) in predicting the efficacy of rhLTα-Da. Results: Between September 2010 and May 2013, 150 patients were enrolled. Baseline patients characteristics were similar between arms. No significant difference in either PFS or ORR was observed between these arms. The median PFS was 3.9 months (95% confidence interval [CI]: 2.9-5.3 months) in arm A, 5.7 months (95% CI: 3.2-6.8 months) in arm B, and 4.9 months (95% CI: 3.1-6.1 months) in arm C (P = 0.248); the ORR was 27.1% in arm A, 46.8% in arm B, and 41.7% in arm C (P = 0.073). However, among patients with low levels of serum TNFR-II, the median PFS was significantly longer in arm B than in other two arms (7.2 months [95% CI: 5.1-8.6 months] in arm B vs. 3.5 months [95% CI: 1.7-5.5 months] in arm A [P= 0.022] and 4.0 months [95% CI: 3.2-6.3 months] in arm C [P = 0.027]). The addition of rhLTα-Da to PFdidn't add AEs statistically. Conclusions: Although the primary endpoint was not met, the addition of high-dose rhLTα-Da to PF regimen may prolong PFS in mESCC patients with low levels of serum TNFR-II. Further prospective study in selected patients is warranted. Clinical trial information: ChiCTR-TRC-11001197.
BibTeX
@article{li2016efficacy,
  author = {Yuhong Li and Wenqi Jiang and Feng‐Hua Wang and Guoping Sun and Jianhua Chen and Lin Cheng and Wei Liu and Rongsheng Zheng and Jia Chen and Helong Zhang and Haitao Lan and Jun Qi and Yangqing Liu and Yanming Deng and Heng Zhao and Jian Xiong and Qing Xu},
  title = {{Efficacy and safety of rhLTα-Da with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-labelled, controlled, phase IIb trial.}},
  journal = {Journal of Clinical Oncology},
  year = {2016},
  doi = {10.1200/jco.2016.34.15\_suppl.4036},
}

Loading related content...

Figure